The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million.
GW Pharma trades on the Nasdaq under the ticker symbol GWPH.
Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement
Latest Headlines
- Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact
- Massachusetts cannabis processor fined $120,000 for using excess ethanol
- Lawsuit over California marijuana deliveries continues
- Michigan cannabis worker allegedly licked pre-rolls, sparking vast recall
- Illinois urged to apply adult-use marijuana tax revenue to social equity
- Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact
- Polish authorities detain cannabis industry executive and regulator
- Australia sees record month for medical cannabis approvals
- With all licenses reinstated, CannTrust aims for cannabis product relaunch
- Bermuda’s consultations on recreational cannabis bill generally supportive
Stay Informed